Pfizer is being sued by Moderna for using the Covid-19 vaccine on patents.

In their complaint, Moderna claimed that Pfizer and BioNTech had stolen several important aspects of its technology.

manufacturer of the Covid-19 vaccine Moderna accuses its biggest rivals of stealing its technology in order to create their own vaccine, and is suing Pfizer and the German pharmaceutical company BioNTech.

manufacturer of the Covid-19 vaccine Moderna accuses its biggest rivals of stealing its technology in order to create their own vaccine, and is suing Pfizer and the German pharmaceutical company BioNTech.

Moderna asserted on Friday that the Comirnaty vaccine from Pfizer and BioNTech violates patents it filed to safeguard the technology underlying its preventative injection, Spikevax, several years ago. The business sued for patent infringement in a German court as well as the U.S. federal court.

Considering that their vaccine is founded on private technology created from both BioNTech and Pfizer, Pfizer was shocked by Moderna's complaint, according to Pfizer spokeswoman Pam Eisele.

Pfizer Inc., with headquarters in New York, would "vigorously defend" itself against any claims made in the case, she claimed in an email. BioNTech didn't answer right away.

Moderna said in a case submitted on Friday to the U.S. District Court for the District of Massachusetts that "when Covid-19 arose, neither Pfizer nor BioNTech had the level of experience Moderna had with generating mRNA vaccines for coronaviruses."

innovative technology

The genetic coding for the spike proteins that covers the coronavirus's surface is injected by the mRNA vaccinations. This code, known as the mRNA, is contained in a tiny ball of fat and tells the cells in the body to produce some benign spike copies that help the immune system develop the ability to identify the actual virus.

the cause of the litigation

In its complaint, Moderna claimed that Pfizer and BioNTech had stolen several essential elements of its technology, including the "exact same chemical alteration to its mRNA that Moderna researchers first devised years ago" and later used in Spikevax.

It claimed that it understands the value of having access to vaccines and is not attempting to have Comirnaty taken off the market. Additionally, no injunction to stop further sales is being requested.

In 2020, Moderna declared that as long as the pandemic persisted, it would not enforce any of its Covid-19-related patents. However, the business announced in March that it would update that commitment as vaccination supplies around the world improved.